Vaccinex Sees Mixed Signals In Huntington’s Study

Pepinemab Missed Key Endpoints In Phase II Trial

 
• By Joseph Haas
  
Hand flip wooden cube with the word PLAN A to PLAN B on white background. Business concept
With mixed data in Huntington's, Vaccinex turns attention to Alzheimer's

More from Clinical Trials

More from R&D